Coronavirus disease 2019 (COVID-19) was declared a global pandemic by the World Health Organization (WHO) on March 11, 2020. Patients with COVID-19 have an increased risk of mortality and multiple organ failure and debilitating symptoms including dyspnea, chest pain, and fatigue ([@R1]--[@R6]). The pandemic has imposed an unprecedented burden on healthcare systems worldwide, with demand for critical care exceeding capacity in some countries ([@R7]--[@R10]). As yet, there are no treatments proven to be effective ([@R11]).

In response to this crisis, clinical trials in COVID-19 have been initiated very rapidly. As of July 6, 2020, 4,098 trials were registered in the WHO International Clinical Trials Registry ([@R12]). The use of evidence from these trials to inform clinical decision-making is problematic, in part because the heterogeneity of outcomes reported across trials precludes robust comparisons across trials. Also, the outcomes of relevance to patients and clinicians may not always be reported. In a WHO review of outcomes used in 84 registered trials in COVID-19, six trials (7%) included mortality and 25 (30%) included lung injury indicated by oxygen saturation, respiratory failure, chest imaging, and oxygenation index ([@R13]).

The problems with heterogenous reporting of outcomes in trials are well known. Core outcome sets have been established to ensure that critically important outcomes are consistently reported in all trials ([@R14], [@R15]). There have been three initiatives to identify core outcomes for trials in COVID-19, all of which have established mortality and respiratory failure as core outcomes ([@R13], [@R16]--[@R18]). Mortality and respiratory failure in hospitalized patients were identified by all three initiatives ([@R19]). However, the prior initiatives involved a limited number of stakeholders (\~70 to 135) and countries (1--25) ([@R13], [@R16], [@R18], [@R19]). Only one initiative involved patients and the public, who were all from China. This is of concern as patient-important outcomes are often omitted from trials ([@R20]).

To ensure broad inclusion of stakeholders globally, including patients and the general public, the COVID-19-Core Outcomes Set (COS) project was launched in March 2020 to establish a core outcomes set for trials in people with confirmed or suspected COVID-19 ([@R21]) across the full spectrum of disease and in all settings. The process was based on the Core Outcome Measures in Effectiveness Trials (COMET) framework ([@R14]) and involved a systematic review of outcomes reported in published and registered trials, an international online survey conducted in five languages involving 9,289 respondents from 111 countries ([@R22]) and four consensus workshops. In this report, we summarize the workshop discussions on establishing the core outcomes set and present the final COVID-19-COS core outcomes set.

METHODS
=======

Overview and Context
--------------------

Four online COVID-19-COS consensus workshops were convened from 14 to 15 of April 2020 using the video conferencing platform, Zoom, to discuss a proposed set of core outcomes that were identified from a prior international survey that involved 9,289 respondents (people with suspected or confirmed COVID-19 and their family members \[*n* = 776\]), members of the general public (*n* = 3,631), and health professionals (*n* = 4,882) from 111 countries ([@R22], [@R23]). The survey was conducted in five languages. At the workshop, we presented the top 10 rated outcomes identified by the survey respondents: mortality, respiratory failure, pneumonia, organ failure, lung function, lung scarring (fibrosis), sepsis/septic shock, shortness of breath, oxygen saturation, and hospitalization. These outcomes had a mean score greater than 7.5 (on a nine-point Likert scale, 7--9 being of critical importance), median greater than or equal to 8, with greater than 70% of respondents rating the outcome from 7 to 9 in each of the three stakeholder groups (patients/family members, public, and health professionals). The survey will be published separately.

Participants and Contributors
-----------------------------

We invited people with suspected or confirmed COVID-19 18 years old and over, family members, members of the general public, and health professionals (physicians with expertise in critical care medicine, pulmonary and respiratory disease, infectious disease, emergency medicine, cardiology, nephrology, nurses, multidisciplinary clinicians, researchers, funders, and policy makers) through the Steering Committee and Investigators and social media, with invitations sent by e-mail. In total, 95 attendees (including 17 with suspected/confirmed COVID-19) from 21 countries (Australia, Austria, Belgium, Brazil, Canada, Chile, China \[mainland China and Hong Kong SAR\], France, Germany, Italy, Japan, Portugal, Republic of Ireland, Saudi Arabia, South Africa, South Korea, Spain, Switzerland, United States, United Kingdom) participated. The full list of workshop attendees and investigators is provided in the acknowledgments.

Workshop Program and Process
----------------------------

During each workshop, we presented the COVID-19-COS process, results from the survey, and a proposed core outcomes set. The attendees were then allocated into two virtual breakout rooms, each including people with COVID-19, members of the general public, and health professionals. The facilitator asked participants to discuss the proposed core outcomes. For feasibility of implementation, it was recommended that the core set should be comprised of three to five outcome domains, including at least one patient-reported outcome ([@R14], [@R24]). All 38 outcomes in the survey, including those added by survey respondents were shown to the participants. The five outcomes proposed for the core outcomes set presented at the workshop were as follows: mortality, respiratory failure, multiple organ failure, sepsis, and shortness of breath. Lung function, lung fibrosis, and pneumonia that were rated highly in the survey were not included in the proposed core outcomes set because of the overlap with respiratory failure and shortness of breath. All discussions were recorded and transcribed verbatim. The transcripts were imported into HyperResearch (ResearchWare Inc, version 3.0, Randolph, MA) for analysis. Using thematic analysis ([@R25]), author (A.T.) inductively identified themes on establishing core outcomes for trials in people with confirmed or suspected COVID-19. All attendees and investigators received the draft report, which included the final recommended COVID-19-COS core outcomes set (**Fig. [1](#F1){ref-type="fig"}**), and were invited to provide feedback by e-mail.

![COVID-19-Core Outcomes Set (COS).](ccm-48-10.1097.ccm.0000000000004585-g001){#F1}

RESULTS
=======

The themes are described in the following section with selected quotations from the workshops provided in **Table [1](#T1){ref-type="table"}**. **Box 1** outlines the recommendations from the consensus workshops.

###### 

Box 1. Summary of the Workshop Recommendations to Consider in Establishing Core Outcome Domains for Trials in People With Suspected or Confirmed Coronavirus Disease 2019
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###### 

Selected Quotations
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Responding to the Critical and Acute Health Crisis
--------------------------------------------------

### Focus on Saving Lives.

Mortality was consistently identified as the most important outcome, which reflected the pressing primary goal of "keeping patients alive" and managing the "crisis" of the global pandemic. Death was identified as the worst outcome and was "far and away driving action and concern about \[COVID-19\], the major thing we're trying to avert from the point of view of interventions."

### Preventing Life-Threatening Complications.

The high priority placed on mortality, respiratory failure, and multiple organ failure resonated with the urgent need to manage severe and critical cases of COVID-19. It was suggested that respiratory failure should be defined as "'severe' respiratory failure because that's what everybody is so much afraid of, to end up at the ICU and on the ventilator." Some patients were concerned that many who were placed on a ventilator did not recover. These severe outcomes were particularly feared among vulnerable populations---"multiorgan failure is a big one because I'm one of the immunocompromised; I'm in that high-risk category of COVID having severe reactions."

Capturing Different Settings of Care
------------------------------------

### Minimizing Burden on Hospitals.

The need to "protect the healthcare system" supported the inclusion of outcomes relevant to the hospital setting. Some countries encountered difficulties in mobilizing healthcare resources during the early phase of the pandemic. Respiratory failure was important because it determined if patients would require admission to intensive care. Health professionals suggested that the use of hospital resources should be embedded in how the core outcomes were defined---"kidney failure could be defined as need for kidney replacement therapy. Respiratory failure could be defined based on what respiratory support you require."

### Recognizing Events Occurring in Community Contexts.

Many people with COVID-19 were managed at home or in the community (e.g. aged care facilities), thus including outcomes relevant outside of the hospital setting was warranted. Patients who were not hospitalized emphasized that severe symptoms, including shortness of breath, fatigue, and headache, as well as recovery, were important---"there might be a distinction between people who are hospitalized and critically ill versus people who are managing it at home and recovering." In some countries, people could not be admitted to ICU owing to limited hospital capacity; therefore, some participants advised that COVID-19 related mortality "needed to include out-of-hospital deaths."

### Ensuring Relevance and Feasibility in Low-Resource Regions.

In some settings, particularly in low-income countries, mechanical ventilation, and extracorporeal membrane oxygenation were not available---"we are getting away in many instances with proning a patient \[positioning a patient flat on the stomach with the chest and head facing down\], without necessarily invasively ventilating them; these are patients who have got saturations of 70 and 80%, where ordinarily in any other context those patients would have been invasively ventilated." Therefore, the definition and measure of respiratory failure also needs to also be applicable in low-income countries. Multiple organ failure was highly relevant in low- and middle-income countries---"we have seen a lot of patients with multiple organ failure because these patients arrived late in the hospital, because sometimes they are stuck in the other parts of the healthcare system \[when they should be in ICU\]."

Encompassing the Full Trajectory and Severity of Disease
--------------------------------------------------------

### Addressing Prognostic Uncertainty and Long-Term Concerns.

The long-term impacts of COVID-19 are relevant. However, the specific outcomes of most importance were uncertain because of the lack of data on longer-term outcomes. Patients wanted to know about time to recovery---"what is worrying me now is post viral fatigue and recovery, because it's been a very long time since I've spent two weeks in bed, and I'm showing no signs of being strong enough to even function in the house, never mind go back to work. That's what's concerning me about a long-term recovery is that kind of post viral thing." Health professionals suggested that recovery should be a core outcome---"I was surprised to not see recovery as a core outcome in the first category." Participants suggested consideration of ongoing symptoms such as shortness of breath, fatigue, chest pain, and cough---"I'm in day 35 and I'm still struggling with shortness of breath." Some patients were concerned about long-term impacts on lung health (e.g. lung function, lung scarring)---"I am really scared when they do tell me that I can go and get an x-ray, what my lungs are going to show because I've never had that kind of chest pain and shortness of breath before." Long-term outcomes were relevant to make trade-offs in decision-making---"imagine a kind of discrete choice experiment to decide, 'do we ventilate harder to get the patient off the ventilator sooner, but risk more pulmonary fibrosis long-term?' There's a balance between the acute outcomes and the long-term consequences."

### Applicable to Mild and Moderate Disease .

Shortness of breath, oxygen saturation, pneumonia, recovery, and fatigue were suggested to be important for people who did not have severe COVID-19---"if I were asymptomatic and in a trial I certainly would be interested in shortness of breath, but I'd also be interested in whether I needed to get admitted to the hospital." To cover the spectrum of disease severity, participants recommended that outcomes related to postacute illness recovery be included---"absence of disease \[recovery\], which surely is one of the outcomes that one is trying to accomplish when one is conducting a trial is to cure people and to get rid of the disease." Patients referred to recovery as being able to do usual activities---"There will be a period of recovery. This week I can have a shower and go downstairs and have breakfast and I'm not short of breath, whereas last week I couldn't do that. So that's an indicator of some measure of recovery."

Distinguishing Overlap, Correlation, and Collinearity
-----------------------------------------------------

### Symptoms Having Distinct Value.

Shortness of breath was a symptom that was "debilitating," "lasted the longest," and prevented the ability to do usual daily tasks and thus captured an important aspect of the patient experience of COVID-19. It was recognized that shortness of breath could have value as a prognostic indicator because "a chest radiograph may not always detect pneumonia in COVID-19 and some of these patients who have shortness of breath can progress quickly to respiratory failure, so it may be the only sign of respiratory failure or pneumonia." Health professionals advised that shortness of breath could be a symptom of COVID-19 and also related to ICU-acquired diaphragmatic weakness.

### Clarifying Causal Pathways.

Health professionals noted that sepsis was included in the definition of multiple organ failure---"sepsis is defined as organ failure due to infection. All the patients have infection, by definition." Respiratory failure could "dominate the category of multiple organ failure." However, some argued that multiple organ failure was justifiable as a core outcome because kidney damage or cardiovascular disease had been observed in people with COVID-19. Lung outcomes (respiratory failure, lung function, lung scarring, and pneumonia) were all of high priority, however were on a continuum inclusive of respiratory failure.

Recognizing Adverse Events
--------------------------

It was expected that "we are going to be trialling a lot of novel interventions" and participants urged awareness of the "variation in approach to treatment around the world and the way that that's evolving quite rapidly." However, without compelling cases for effective treatments at present and with little commonality across different interventions (e.g. drug classes), potential intervention-specific adverse events may be excluded from the core outcomes set.

Being Cognizant of Family and Psychosocial Wellbeing
----------------------------------------------------

Due to the potentially severe nature of COVID-19 and requirement for quarantine, emphasis was placed on the profound impacts on the psychosocial wellbeing of patients and their families. Being in isolation was thought to exacerbate sickness, deterioration, depression, and anxiety for patients and their families---"we've seen people where they've had to stand outside and speak to their loved one on a walkie talkie to say goodbye because they're dying." Patients experienced guilt, fear, and depression related to infecting others.

The COVID-19-COS Core Outcomes Set
----------------------------------

The recommendations (Box 1) arising from the workshop were used to finalize the core outcomes set based on review by the Steering Committee and investigators. Sepsis was moved from the initial core outcomes set into Tier 2 because of overlap with multiple organ failure. Lung function, lung fibrosis, and pneumonia remained in Tier 2 to avoid overlap with respiratory failure and shortness of breath. Shortness of breath was retained in the core outcomes set because it was the most important patient-reported outcome and was a symptom relevant across the spectrum of COVID-19 and across the full trajectory of an individual's disease course. It was strongly and consistently recommended that a longer term outcome should be included. However, the top 10 ranked outcomes from the survey comprised only of acute and severe outcomes. Recovery (defined in the survey as how long it takes to recover, i.e., feel better, no longer having symptoms) was the highest rated long-term outcome and was moved from Tier 2 into the core outcomes set as in response. Six outcomes relating to symptoms and psychosocial and family impact (based on those that were highest ranked in the survey---chest pain, cough, depression, fatigue, impact on family, life participation) were moved from Tier 3 to Tier 2. The final COVID-19-COS core outcome domains are shown in Figure [1](#F1){ref-type="fig"}.

DISCUSSION
==========

Overall, people with suspected or confirmed COVID-19, family members, the public, and health professionals agreed that mortality, respiratory failure, and multiple organ failure were the most critically important outcomes that should be core outcomes for all trials in COVID-19. These outcomes reflected the immediate goals of saving lives, preventing life-threatening complications, and protecting the healthcare system that were paramount in the current pandemic. Shortness of breath was identified as a persistent and debilitating symptom that impaired the ability to perform daily activities, was relevant to all levels of disease severity, and provided meaningful information about the patient experience of COVID-19. This symptom was also seen to have potential value as a diagnostic and prognostic indicator for lung health including pneumonia and respiratory failure or as a long-term outcome, for example, a sign of ICU-acquired weakness. All stakeholders emphasized the importance of capturing the full severity and trajectory of disease in the core outcomes set, including long-term outcomes. Therefore, recovery was included in the core outcomes set.

The workshop discussions and recommendations informed the selection of the core outcome domains to be reported in trials in people with confirmed or suspected COVID-19: mortality, respiratory failure, multiple organ failure, shortness of breath, and recovery (Fig. [1](#F1){ref-type="fig"}, Panel 1).

Mortality, respiratory failure, multiple organ failure, and recovery have been identified as core outcomes for COVID-19 by recent initiatives ([@R13], [@R16], [@R17]). The WHO core outcomes set for clinical research included three domains: survival (all-cause mortality at hospital discharge or 60 d), viral burden, and clinical progression (including need for interventions for respiratory and multiple organ failure) ([@R13]). The COS-COVID core outcomes set included viral load, hospitalization, oxygen saturation, respiratory failure (duration of mechanical ventilation), and mortality ([@R16]). Qiu et al ([@R17]) identified eight outcome domains, including recovery time and mortality, respiratory outcomes, and non-specified symptoms. The COVID-19-COS core outcomes set includes the patient-reported outcome of shortness of breath, which has not been previously identified. Shortness of breath is a common and distressing symptom in people with lung disease and a potential predictor of mortality ([@R26]). A study in pulmonary rehabilitation in patients with chronic obstructive pulmonary disease identified shortness of breath as one of the most important outcomes for patients, caregivers, and health professionals ([@R27]). An international Delphi survey involving researchers, clinicians, patients/caregivers, and funders identified pulmonary symptoms as a core domain for survivors of acute respiratory failure after discharge from the hospital ([@R28]).

Further work is needed to identify valid core outcome measures for the core outcome domains that can be feasibly implemented in all trials in people with suspected or confirmed COVID-19. This will involve the review of established definitions and measures (including core measures) for mortality, respiratory failure, multiple organ failure, and recovery and possible pilot and validation work to establish a patient-reported outcome measure for shortness of breath that is psychometrically robust and of minimal burden to implement.

CONCLUSIONS
===========

With the rapidly growing body of evidence from clinical trials, urgent implementation of core outcomes in trials in COVID-19 can help to improve the consistency of reporting outcomes that are critically important to patients, family members, the public, and health professionals. This can better inform decision-making in the context of this pandemic and strengthen the value of trials to inform the management of people with suspected and confirmed COVID-19 and hopefully improve patient outcomes.

###### 

COVID-19-Core Outcomes Set (COS) Workshop Investigators (Attending and Nonattending Contributors) for Group Authorship
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